Relationship of Oxidant and Antioxidant Markers to Asthma Severity in Egyptian Asthmatic Children by EL-Alameey, Inas R. et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on August 10, 2017 as https://doi.org/10.3889/oamjms.2017.149 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                        1 
 
ID Design 2012/DOOEL Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
https://doi.org/10.3889/oamjms.2017.149 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Relationship of Oxidant and Antioxidant Markers to Asthma 
Severity in Egyptian Asthmatic Children 
 
 
Inas R. EL-Alameey
1
*, Gihan A. Fathy
1
,
 
Mones M. Abu Shady
1
, Alaa Ali
1
,  Hanan A. Fathy
2
, Eman R. Youness
3
, Soha A. 
Nasr
4
 
 
1
National Research Centre, Child Health Department, Egypt; 
2
National Center for Radiation Research and Technology, 
Pediatric Department, Egypt; 
3
National Research Centre, Biochemistry, Egypt; 
4
National Research Centre, Clinical 
Pathology, Egypt 
 
Citation: El-Alameey IR, Fathy G, Shady MA, Ali A, 
Fathy H, Younis E, Nasr S. Relationship of Oxidant and 
Antioxidant Markers to Asthma Severity in Egyptian 
Asthmatic Children. Open Access Maced J Med Sci. 
https://doi.org/10.3889/oamjms.2017.149 
Keywords: asthmatic children; asthma severity; 
antioxidant markers; an oxidant; Relationship. 
*Correspondence: Inas El-Alameey, National Research 
Centre, Child Health Department, Egypt. Scopus author 
ID: 56205614600. http://orcid.org/0000-0002-0168-7663 
E-mail: inasno@hotmail.com  
Received: 20-Apr-2017; Revised: 18-Jun-2017; Accepted: 
20-Jun-2017; Online first: 10-Aug-2017 
Copyright: © 2017 Inas El-Alameey, Gihan Fathy, Mones 
Abu Shady, Alaa Ali, Hanan Fathy, Eman Younis, Soha 
Nasr. This is an open-access article distributed under the 
terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 
4.0). 
Funding: This research did not receive any financial 
support. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
Abstract  
BACKGROUND: Asthma is a chronic airway disease which is characterized by oxidant antioxidant imbalance 
with the generation of oxidative stress related mediators. 
AIM: The study aimed to evaluate the role of asymmetric dimethylarginine, and malondialdehyde as oxidant 
markers and serum paraoxonase activity as an antioxidant marker in asthma, and to determine their relationship 
to the asthma severity and lung function among asthmatic children in Egypt. 
PATIENTS AND METHODS: This case control study was conducted on sixty patients with asthma compared with 
sixty apparently healthy children of matched age and sex. 
RESULTS: Serum concentrations of oxidant markers as asymmetric dimethylarginine and malondialdehyde were 
significantly increased in asthmatic patients while anti-oxidant marker as paraoxonase activity was significantly 
decreased compared to healthy controls (P < 0.05). ANOVA test revealed highly significant elevation of the serum 
concentrations of oxidant markers while anti-oxidant marker was significantly decreased in severe asthmatic 
patients (P < 0.001) compared to the patients with moderate and mild asthma respectively. Serum 
malondialdehyde concentration was a strong predictor of asthma severity by multiple regression analysis (P < 
0.05). 
CONCLUSION: The study revealed an imbalance between oxidative and antioxidant defence systems in 
asthmatic children. Serum concentration of malondialdehyde was the most predictive biomarker having a 
significant association with asthma severity.  
 
 
 
Introduction 
 
Asthma is the most frequent chronic 
inflammatory airway disease in children [1]. Its 
prevalence has increased during the last four 
decades, affecting more than one-third of children 
from the general population [2, 3]. Although the exact 
mechanism of the pathogenesis of asthma is 
unknown, asthma is characterized by oxidant-
antioxidant defence systems imbalance with 
increased generation of oxidative stress related 
mediators in asthmatic patients [4] that cause an 
oxidative injury in asthma, and increased airway 
reactivity [5, 6].  
Little is known about the role of asymmetric 
dimethylarginine (ADMA) in the pathogenesis of 
asthmatic airway inflammation [7]. The lung is a major 
source of ADMA [8] that can promote oxidative stress 
by a reduction in nitric oxide synthesis which would 
result in higher levels of peroxynitrite, that causes 
oxidative cell damage, and exacerbate airway 
inflammation [9]. ADMA can modify lung function, 
increase airway hyperreactivity even in non-inflamed 
airways, and promote lung collagen production and 
deposition [10]. Increased ADMA in serum has been 
found to be associated with the severity of symptoms 
of asthma in obese adults [11], and endothelial 
dysfunction [12-13].  
Malondialdehyde (MDA) is an oxidant marker 
of pulmonary oxidative stress, and lipid peroxidation 
[14]. Paraoxonase, an antioxidant enzyme may play a 
protective role in asthma. It hydrolyzes lipid peroxides 
and prevents low-density lipoprotein (LDL) oxidation 
[15].  
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Therefore, the aim of our present study was to 
evaluate the role of ADMA, malondialdehyde, and 
paraoxonase activity in asthma among asthmatic 
children and to determine the relationship of these 
biomarkers to the underlying aetiology, the clinical 
severity and lung function among asthmatic children in 
Egypt.  
 
 
Subjects and Methods 
 
Subjects 
This descriptive cross sectional case control 
study was carried out on a total of sixty asthmatic 
children aged between 6 to 12 years (mean 8.35± 3.53 
years) were studied. They were classified according to 
the severity of asthma that was determined using 
pulmonary function tests into three subgroups as 
follows; twenty patients had mild persistent asthma in 
group I, twenty patients had moderate persistent 
asthma in group II, and twenty patients had severe 
persistent asthma in group III. The inclusion criteria for 
selection included all known asthmatic patients who 
had been regularly attending the Pediatric Allergy and 
Immunology clinic, Abo El-Rish Children’s Hospital, 
Cairo University, Egypt. Exclusion criteria included 
obese children, the presence of chronic heart, liver 
and kidney diseases, concomitant inflammatory 
disease such as infections and autoimmune disorders, 
and Diabetes mellitus. Patients taking antioxidant 
drugs, vitamins, diuretics, hormone replacement 
therapy were also excluded. All the children involved 
in the study did not have any symptoms of lower or 
upper respiratory tract infection or asthma 
exacerbation within the previous four weeks. 
Sixty apparently healthy non-asthmatic 
children from public schools of matched age and sex 
were recruited as a control group with no history of 
atopic dermatitis, or allergic rhinitis/ conjunctivitis. 
They were selected from the outpatient's clinic at the 
National Research Center. They were attending the 
clinic for follow-up. The study was approved by the 
Research Ethics Committee of the National Research 
Center with ethical approval number 17022. Written 
informed consent was obtained from the parents of 
the participating patients and controls. 
 
Methods 
All patients and controls were subjected to a 
complete physical examination and anthropometric 
measures. All measurements were made according to 
techniques described in the Anthropometric 
Standardization Reference Manual [16]. Weight (in kg) 
was taken using a digital scale (Seca, Hamburg, 
Germany) to the nearest 0.1 kg. Height (in cm) was 
measured using a Seca 225 stadiometer to the 
nearest 0.1 cm with the children dressed in minimal 
clothes and without shoes. Each measurement was 
taken as the mean of three consecutive readings 
following the recommendations of the International 
Biological program [17]. BMI and growth percentiles 
for all children were calculated based on the WHO 
growth standards with the help of Anthro-Program 
[18]. 
Information on age, sex, parental 
consanguinity, family history of bronchial asthma, 
duration of illness and treatment modalities were 
collected via a questionnaire from parents. Patients 
were diagnosed according to the clinical 
manifestations of asthma (a cough, wheezing, 
shortness of breath, and exercise intolerance) 
according to GINA [19], and the clinical severity of the 
asthma was determined by dynamic spirometry. 
Dynamic spirometry (Master screen Pneumo, 
Erich Jaeger GmbH, Germany) was performed in all 
the patients and the healthy controls. The following 
data were obtained; forced vital capacity FVC (litre), 
forced expiratory volume in the first, second FEV1 
(litre), FEV1/FVC ratio or FEV1%. For every 
parameter obtained, actual and predicted values for 
age, sex, height, weight and percentage (%) of the 
predicted were calculated. The highest values of three 
forced expiratory manoeuvres were used. The ratio 
FEV1/FVC is a measure of airflow obstruction. These 
measurements were performed according to the 
standards of the European Respiratory Society and 
the American Thoracic Society [20].  
Skin prick testing for aeroallergen sensitivity 
was done using lancets (Staller point, Paris, France) 
providing a standard puncture of 1 mm. Commercial 
allergen solutions manufactured by Allergopharma 
(Joachim Ganzer KG, Reinbeck, Germany) were used 
for the skin test. Forty-four different allergens 
consisting of house dust mite, grass, wild grass, tree 
pollens, fungi, animal dander, and insects were 
tested. Test sites were evaluated 20 min after allergen 
application using European Academy of Allergy and 
Clinical Immunology criteria [21].  
Overnight fasting venous blood samples were 
collected from all patients and controls into empty 
tubes, and the separated serum was stored at -80 ºC 
until they were used. Serum ADMA concentrations 
were determined by Sandwich- enzyme linked 
immunosorbent assay (ELISA) according to the 
method described by Schulze et al., [22]. In addition, 
malondialdehyde measurement was assayed 
according to the method described by Hunter et al., 
[23], and results are expressed as nmol/ml. 
Paraoxonase activities were measured according to 
Gan et al., [24]. Serum paraoxonase activity was 
expressed as U/L. The cutoff value was calculated 
from healthy control samples. Quantitative 
determination of serum total immunoglobulin E (IgE) 
was performed using ELISA according to the 
manufacturer’s guidelines [25]. Also, C-reactive 
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protein and erythrocyte sedimentation rate were also 
assayed for all children. 
 
Statistical Analysis 
  Statistical analyses were performed using the 
SPSS statistical package software for Windows 
version 21 (SPSS Inc., Chicago, Illinois, USA). 
Parametric variables are expressed as the mean ±
SD. Differences between parametric variables among 
the controls and the studied patient's groups were 
analysed using two tailed unpaired t-tests. Pearson’s 
correlation coefficients were used to evaluate 
correlations between the data exhibiting parametric 
distribution. The comparison between groups was 
performed with one-way analysis of variance 
(ANOVA). Multiple regression analysis was performed 
to examine the relationship between serum levels of 
asymmetric dimethylarginine, malondialdehyde and 
paraoxonase activity with asthma severity. A P value 
< 0.05 was considered significant and p < 0.005 was 
considered highly significant.  
 
 
Results 
 
A total of sixty asthmatic children aged 
between 6 to 12 years (mean 8.35± 3.53 years) were 
studied. Positive family history of asthma was present 
in 15 patients (25%), and positive history of recurrent 
hospitalization was present in 18 patients (30%). 
According to the parents' history, none of them was 
exposed to secondhand smoke.  
Table 1: Comparison of anthropometric measures, pulmonary 
function parameters, and laboratory findings of the studied 
patients and the control groups 
Variables Total patients 
group 
N = 60 
Control 
Group 
N = 60 
Total Patients 
vs controls 
Mean ± SD Mean ± SD P-value 
 
Anthropometric 
measures 
BMI 19.27 ± 3.05 17.35 ± 1.98 0.90 
Height/age percentile 13.98 ± 15.72 39.05 ± 5.18 0.000** 
Weight/age percentile 40.06 ± 24.24 42.15 ± 14.73 0.95 
Pulmonary 
function 
parameters 
FVC (%  of predicted) 71.9 ± 1.31 95.28 ± 2.65 0.000** 
FEV1 (%  of predicted) 72.6 ± 1.44 95.4 ± 2.47 0.000** 
FEV1/FVC ratio 72.6 ± 1.44 94.96 ± 2.73 0.000** 
 
 
Laboratory 
findings 
Serum  paraoxonase  
(U/ml) 
143.23 ± 18.67 212.14 ± 19.15 0.000** 
Serum MDA (nmol/ml) 2.48 ± 0.59 1.23 ± 0.19 0.000** 
Serum  ADMA (mg/dl) 2.96 ± 0.83 1.17 ± 0.45 0.001** 
Serum IgE (U/ml) 51.7 ± 16.56 8.45 ± 5.46 0.000** 
ESR (mm/hr) 18 ± 3.41 4.37 ± 0.86 0.000** 
CRP(mg/ml) 51.7 ± 16.56 4.5 ± 0.81 0.000** 
*Significant difference at p < 0.05, **highly significant difference at p < 0.005. 
 
The mean BMI and weight for age percentile 
of the studied patients were within normal range. The 
mean height for age percentile of the studied patients' 
group was highly significant lower compared to the 
control group (13.98 ± 15.72 versus 39.05 ± 5.18 
respectively, P < 0.001). The mean forced vital 
capacity (FVC), forced expiratory volume in one 
second (FEV1) and FVC/FEV1 ratio of the total 
patient's group was found to be highly significantly 
lower compared to the control group (P < 0.05). 
Serum concentrations of ADMA, MDA, IgE, ESR, and 
CRP were highly significantly increased among 
asthmatic patients compared to healthy controls (P < 
0.001). Serum paraoxonase activity was significantly 
decreased in asthmatic patients compared to healthy 
controls (P < 0.05) as shown in Table 1.  
The studied patients were divided according 
to the degree of severity (mild, moderate, and severe). 
Significant differences in height for age percentile 
between the three groups with the highest value were 
present in severe asthmatic patients (F = 3.35, P < 
0.05). No significant differences were present 
between patients' subgroups as regards the mean 
BMI, and weight for age percentiles (P > 0.05). 
ANOVA test revealed highly significant elevation of 
the serum concentrations of ADMA, MDA, and CRP in 
severe asthmatic patients compared to patients with 
moderate and mild asthma respectively (P < 0.001). 
The mean serum paraoxonase activity was found to 
be highly significantly lower in the patients with severe 
asthma compared to those with moderate and mild 
asthma (P < 0.05), as shown in Table 2. Figure 1 
showed the comparison of laboratory findings of the 
studied patients' subgroups. 
Table 2: Comparison of the anthropometric measures, and 
laboratory findings of the studied patients' subgroups 
(ANOVA) 
 
Variables 
Mild- 
(group I) 
N = 20 
moderate 
(group II) 
N = 20 
Severe 
(group III) 
N = 20 
F P-value 
Mean±SD Mean±SD Mean±SD 
Anthropo-
metric 
measures 
BMI 19.48±2.72 19.26±3.78 19.14±2.79 0.036 0.965 
Height / age 
percentile 
21.05±18.83 13.91±9 10.64 ±8.75 3.35 0.048** 
Weight / age 
percentile 
22.36±16.82 29.44±22.52 36.29± 29.08 1.22 0.306 
Laboratory 
findings 
Serum 
paraoxonase 
(U/ml) 
149.79±19.96 142.52±13.85 135.49±18.21 2.31 0.049* 
Serum MDA 
(nmol/ml) 
2.07±0.15 2.44±0.46 3.07±0.7 12.59 0.000** 
Serum  ADMA 
(mg/dl) 
1.37±2.5 2.36± 1.43 3.28±1.28 6.96 0.003** 
IgE (U/ml) 46.6± 15.73 37.84±7.93 65.29±10.67 22.69 0.000** 
CRP (mg/dl) 37.84±7.93 55.3±10.67 66.6±15.73 22.69 0.000** 
*Significant difference at p < 0.05; **highly significant difference at p < 0.005. 
Serum concentrations of ADMA and MDA 
were significantly increased with increasing severity of 
asthmatic attack (P < 0.001), while serum 
paraoxonase activity was significantly decreased with 
increasing severity of asthmatic attack (P < 0.05). 
Serum ADMA concentrations were significant 
negative correlated with the percent predicted forced 
expiratory volume in one second (FEV1). Serum MDA 
concentration was significant negative correlated with 
the percent predicted forced vital capacity, and 
FEV1/FVC ratio, while serum paraoxonase activity 
was found to be significant positive correlated with the 
percent predicted forced vital capacity (FVC), and the 
FEV1/FVC ratio (P < 0.05), as shown in Table 3. 
Serum paraoxonase activity was found to be 
significant negative correlated with serum 
concentrations of ADMA, malondialdehyde, IgE, CRP 
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and, ESR. Serum concentrations of ADMA and 
malondialdehyde were significantly positive correlated 
with IgE, CRP and, ESR, as shown in Table 4. 
   
Figure 1: Comparison of laboratory findings of the studied patients' 
subgroups 
 
To confirm the previous correlations, multiple 
regression analysis was done showing the association 
between the different biomarkers studied and disease 
severity in Table 5. Serum concentration of 
malondialdehyde was the only predictive biomarker 
having a significant association with disease severity 
(OR = 11.278, 95% CI = 1.145-111.082 and P = 
0.038).  
Table 3: Correlations between parameters of the pulmonary 
function and serum biomarkers of the oxidative status in the 
asthmatic patients 
Variables FEV1 FVC  FEV1/ FVC ratio 
Serum paraoxonase (U/ml) 0.142 0.38* 0.35* 
Serum MDA (nmol/ml) 0.188 -0.32* -0.33* 
Serum  ADMA (mg/dl) -0.491** -0.007 0.28 
Serum IgE (U/ml) -0.859** -0. 87** -0. 88** 
ESR (mm/h) 0.433** -0.394* -0.0005 
CRP (mg/dl) -0.89 -0.90** -0.92** 
*Significant difference at p<0.05, **highly significant difference at p<0.005. 
 
 
Discussion  
 
Asthma is a chronic airway inflammation 
which characterized by recurrent episodes of 
wheezing and coughing which related to increased 
oxidative stress [2]. To the best of our knowledge, 
there is no available information in the literature 
discussing the role of malondialdehyde, asymmetric 
dimethylarginine, and paraoxonase activity in airway 
inflammatory diseases among asthmatic children in 
Egypt. Therefore, this current study is considered to 
be the first clinical study that was carried out to 
determine the role of these biomarkers in asthma 
pathogenesis and to determine their relationship to 
the underlying aetiology, the clinical severity and lung 
function among asthmatic children in Egypt. 
In our present study, shortness of breath, 
chronic recurrent episodes of wheezing and chest 
tightness, coughing, chest discomfort, and loss of 
appetite were the main symptoms among children 
with asthma. The symptoms score were significantly 
higher among the patients with severe asthma 
compared to those with mild and moderate asthma. 
This is in agreement with Koterba and Saltoun [26].  
Table 4: Correlations between the laboratory findings of the 
studied patients 
Variables Serum  
MDA 
Serum 
ADMA 
Serum 
IgE 
 
ESR 
 
CRP 
Serum paraoxonase (U/ml) -0.7** -0.4** -0.737** -0.783** -0.761** 
Serum MDA (nmol/ml) 1 0.138 0.688** 0.805** 0.712** 
Serum  ADMA (mg/dl) 0.138 1 0.201* 0.289** 0.218* 
*Significant difference at p < 0.05; **highly significant difference at p < 0.005. 
 
Regarding anthropometric measures, in our 
present study, the mean height for age percentile of 
the studied patients' group was highly significantly 
lower compared to the control group (13.98 ± 15.72 
versus 39.05 ± 5.18 respectively, P < 0.001), and 
were highly significantly lower in the patients with 
severe asthma compared to patients with moderate 
and mild asthma respectively by ANOVA test. This is 
in agreement with Elnady et al., [27], who reported 
that the mean height for age percentile of the 
asthmatic group was highly significantly lower 
compared to the control group. Our explanation is that 
stunting in asthmatic patients could be due to a 
chronic disease condition, and the effect of long-term 
corticosteroid therapy on bone.  
Table 5: Multiple logistic regression between disease severity 
and serum biomarkers 
Variables Β coefficient OR 95% CI P 
Serum paraoxonase (U/ml) -0.036 0.964 0.916-1.015 0.167 
Serum MDA (nmol/ml) 2.423 11.278 1.145-111.082 0.038* 
Serum  ADMA (mg/dl) 0.372 1.451 0.033-644.261 0.905 
Dependent variable: disease severity. *Significant difference at p<0.05. 
 
Our present study revealed a highly 
significantly elevation of the mean serum level ADMA 
among all asthmatic children studied compared to 
controls (P < 0.005). This is in agreement with the 
study conducted by Lau, et al., [28], who reported that 
the concentrations of asymmetric dimethylarginine 
(ADMA) had been increased in serum of adults and 
sputum samples, as well as exhaled breath 
condensates of pediatric patients with asthma,  
compared to controls.  
In our present study, serum ADMA 
concentration was found to be highly significantly 
increased in the patients with severe asthma (P < 
0.001) compared to those with moderate and mild 
asthma, respectively. This is in agreement with Scott 
et al., [29], who mentioned that increased serum 
ADMA had been discovered to be related to the 
severity of asthma. 
In this current study, serum ADMA 
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concentration was found to be significant negative 
correlated with the percent predicted forced expiratory 
volume in one second (FEV1). This argument is 
consistent with the findings of Lara, et al., [30], and 
Holguin et al., [11], who pronounced that ADMA 
concentration in peripheral plasma samples from 
patients with severe asthma correlated with worsening 
of the symptom scores, predicted FEV1%, and FVC%. 
Also, Carraro, et al., [31] observed the changes in 
pulmonary function testing causing a decline in 
FEV1% predicted in asthmatic patients, together with 
a significant increase in sputum ADMA (P < 0.05), 
especially after allergen challenge in asthmatic 
patients with mild allergic asthma, and concomitant 
with the onset of airways obstruction.  
Serum malondialdehyde concentration is one 
of the most frequently used indicators of lipid 
peroxidation of the membranes that results from 
oxidative damage. This implies that children during an 
acute asthmatic attack are exhibit enhanced lipid 
peroxidation [32]. Given the present data, the serum 
concentration of MDA was highly significantly 
increased in the studied patients compared to controls 
(P < 0.001), and in severe asthma compared to the 
studied patients with moderate and mild asthma (P < 
0.001). Serum MDA concentration showed significant 
negative correlation with the percent predicted FVC 
and FEV1/FVC ratio. Serum MDA level was the most 
predictive biomarker having a significant association 
with asthma severity (P < 0.05). 
In our present study, the mean paraoxonase 
activity of the studied patients was found to be highly 
significantly lower compared to the healthy control 
group, (P < 0.001). This is in agreement with the study 
conducted by Cakmak, et al., [33], who determined 
that the enzyme paraoxonase activity had an 
antioxidant function and was low in asthmatic children. 
Also, our current study is in agreement with the study 
conducted by Can et al., [34] who observed that 
asthmatic patients had reduced paraoxonase activity. 
They explain the evidence of elevated paraoxonase 
activity in asthmatic patients after treatment, may 
indicate that paraoxonase could play a role in asthma. 
Our present study revealed a highly 
significantly lower serum paraoxonase activity in the 
patients with severe asthma compared to those with 
moderate and mild asthma respectively (P < 0.05). Its 
serum activity was positively correlated with the 
percent predicted FVC and FEV1/FVC ratio. It 
became notably decreased with increasing severity of 
asthmatic attack (P < 0.001). Our study is in 
agreement with the study conducted by Górnicka et 
al., [35], who suggested that serum paraoxonase 
activity was significantly decreased with increasing 
severity of the asthmatic attack. 
In our asthmatic children, serum paraoxonase 
activity showed significant negative correlation with 
serum concentrations of ADMA and MDA. It means 
that increased serum oxidative stress mediators as 
ADMA and malondialdehyde concentrations were 
associated with reduced paraoxonase activity in 
asthmatic children supports their role for these 
mediators in asthma pathogenesis (in all, P < 0.05). 
This is in agreement with Ekmekci et al., [36], and 
Kabaroglu et al., [37], who mentioned that an inverse 
relationship between reduced serum paraoxonase 
activity and increased oxidative stress biomarkers in 
asthmatic patients. An increase in oxidative stress and 
a lower in paraoxonase activity may be important 
contributors to the acceleration of the progression of 
attack in asthmatic patients [38]. 
In conclusion, our results revealed that an 
imbalance between oxidative (ADMA, and MDA) and 
antioxidant biomarkers (paraoxonase activity) in 
asthmatic children. Serum malondialdehyde 
concentration was the most predictive biomarker 
having a significant association with asthma severity. 
Early identification of these biomarkers may help in 
identifying those at risk of severe asthma. 
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